BSG and hepatocellular carcinoma: introduced Tet-On inducible CD147-CART cells to treat HCC and found that with the supply of Dox, Tet-On inducible CD147-CART cells could lyse multiple HCC cell lines in vitro and effectively inhibit the growth of cancer cells in the HCC xenograft model (80).